News-Medical.Net Pharmaceutical News

Syndicate content
Latest Pharmaceutical News and Research
Updated: 1 day 16 hours ago

Study finds changes in antiepileptic drug metabolism during different trimesters of pregnancy

Wed, 2018-10-17 19:55
During pregnancy, the numerous physiological changes a woman's body undergoes can alter the way medications are metabolized, the rate at which they are cleared, and their overall effectiveness.
Categories: News

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

Wed, 2018-10-17 07:27
HealthCore, Inc., the outcomes research subsidiary of Anthem, Inc. and Novo Nordisk Inc., which manufacturers the once weekly GLP-1 receptor agonist Ozempic (semaglutide), are working together to launch the first of its kind pragmatic study to understand the benefits of semaglutide as compared with all other available diabetes drugs in a real-world pragmatic clinical trial for Type 2 diabetes - one of the nation's fastest growing chronic diseases.
Categories: News

Misuse of prescription opioids or benzodiazepines associated with suicidal thoughts

Tue, 2018-10-16 23:18
Misuse of prescription opioids or benzodiazepines (such as Xanax) was associated with suicidal ideation in a study of US older adults.
Categories: News

Antidepressant treatment may lead to improvements in sleep quality of patients with depression

Tue, 2018-10-16 23:03
In a study of 15 patients affected by major depressive disorder and complaining of insomnia, initiating treatment with vortioxetine for their depressive symptoms led to significant improvements in subjective sleep quality and daytime sleepiness.
Categories: News

Hundreds of dietary supplements shown to contain unapproved drugs

Tue, 2018-10-16 06:33
An investigation has found that hundreds of over-the-counter dietary supplements contain unapproved pharmaceutical ingredients.
Categories: News

Eisai enters into agreement with Eurofarma for development and sales of lorcaserin in 17 countries

Tue, 2018-10-16 05:13
Eisai Co., Ltd. has entered into an agreement to grant exclusive development and marketing rights for its anti-obesity agent lorcaserin hydrochloride (generic name, product name in the United States: BELVIQ, product name for once-daily formulation in the United States: BELVIQ XR, "lorcaserin") in 17 countries in Latin America and the Caribbean, excluding Brazil, to Eurofarma Laboratorios S.A. which has a business foundation in Latin America.
Categories: News